ES2248806T3 - Derivado de la guanina. - Google Patents

Derivado de la guanina.

Info

Publication number
ES2248806T3
ES2248806T3 ES96900631T ES96900631T ES2248806T3 ES 2248806 T3 ES2248806 T3 ES 2248806T3 ES 96900631 T ES96900631 T ES 96900631T ES 96900631 T ES96900631 T ES 96900631T ES 2248806 T3 ES2248806 T3 ES 2248806T3
Authority
ES
Spain
Prior art keywords
weight
valacyclovir
hydrochloride
valacyclovir hydrochloride
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96900631T
Other languages
English (en)
Spanish (es)
Inventor
Barry Howard Carter
Jane Muse Partin
Peter Gregory Glaxo Wellcome Inc. VARLASHKIN
Richard Augustus Winnike
William Bayne Grubb, Iii
Gregory Alan Conway
Philip George Lake
David Michael Skinner
David James Whatrup
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10768347&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2248806(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Application granted granted Critical
Publication of ES2248806T3 publication Critical patent/ES2248806T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
ES96900631T 1995-01-20 1996-01-19 Derivado de la guanina. Expired - Lifetime ES2248806T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9501178.9A GB9501178D0 (en) 1995-01-20 1995-01-20 Guanine derivative
GB9501178 1995-01-20

Publications (1)

Publication Number Publication Date
ES2248806T3 true ES2248806T3 (es) 2006-03-16

Family

ID=10768347

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96900631T Expired - Lifetime ES2248806T3 (es) 1995-01-20 1996-01-19 Derivado de la guanina.

Country Status (40)

Country Link
US (1) US6107302A (enExample)
EP (1) EP0804436B1 (enExample)
JP (1) JP3176633B2 (enExample)
KR (1) KR100376074B1 (enExample)
CN (1) CN1049893C (enExample)
AP (1) AP662A (enExample)
AR (1) AR002270A1 (enExample)
AT (1) ATE302777T1 (enExample)
AU (1) AU702794B2 (enExample)
BG (1) BG63393B1 (enExample)
BR (1) BR9606768A (enExample)
CA (1) CA2210799C (enExample)
CY (1) CY2531B1 (enExample)
CZ (1) CZ297065B6 (enExample)
DE (1) DE69635106T2 (enExample)
DK (1) DK0804436T3 (enExample)
EA (1) EA000364B1 (enExample)
EE (1) EE03528B1 (enExample)
ES (1) ES2248806T3 (enExample)
FI (1) FI973063A7 (enExample)
GB (1) GB9501178D0 (enExample)
GE (1) GEP20001940B (enExample)
HR (1) HRP960024B1 (enExample)
HU (1) HU222993B1 (enExample)
IL (1) IL116831A (enExample)
IN (1) IN182468B (enExample)
IS (1) IS2268B (enExample)
NO (1) NO315558B1 (enExample)
NZ (1) NZ298851A (enExample)
OA (1) OA10499A (enExample)
PL (1) PL182175B1 (enExample)
RO (1) RO118693B1 (enExample)
RS (1) RS49518B (enExample)
SI (1) SI0804436T1 (enExample)
SK (1) SK285329B6 (enExample)
TR (1) TR199700656T1 (enExample)
UA (1) UA46001C2 (enExample)
UY (1) UY25779A1 (enExample)
WO (1) WO1996022291A1 (enExample)
ZA (1) ZA96449B (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative
PT874631E (pt) * 1996-01-19 2004-04-30 Glaxo Group Ltd Utilizacao de valaciclovir para a manufactura de um medicamento para o tratamento de herpes genital por aplicacao diaria unica
IT1283447B1 (it) * 1996-07-18 1998-04-21 Ind Chimica Srl Processo di preparazione del valaciclovir e relativi intermedi
WO1998031683A1 (en) * 1997-01-17 1998-07-23 Ajinomoto Co., Inc. Novel z-valacyclovir crystals
GB0010446D0 (en) * 2000-04-28 2000-06-14 Glaxo Wellcome Kk Pharmaceutical formulation
HU230384B1 (hu) * 2001-02-24 2016-03-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xantinszármazékok, előállításuk és alkalmazásuk gyógyszerként
SK1592004A3 (sk) * 2001-09-07 2005-03-04 Teva Pharmaceutical Industries Ltd. Kryštalické formy valaciklovírus hydrochlóridu
AU2002348022B2 (en) * 2001-11-05 2006-06-15 Glaxo Group Limited Anhydrous crystal form of valaciclovir hydrochloride
JP2005508993A (ja) * 2001-11-14 2005-04-07 テバ ファーマシューティカル インダストリーズ リミティド バラシクロビルの合成及び精製
WO2004000265A2 (en) * 2002-06-24 2003-12-31 Ranbaxy Laboratories Limited Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
US7407955B2 (en) * 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20050043329A1 (en) * 2002-09-06 2005-02-24 Shlomit Wizel Crystalline forms of valacyclovir hydrochloride
US20050059684A1 (en) * 2002-10-16 2005-03-17 Ben-Zion Dolitzky Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
WO2004035583A1 (en) * 2002-10-16 2004-04-29 Teva Pharmaceutical Industries Ltd. Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
US20060229322A1 (en) * 2002-12-09 2006-10-12 Pau Cid Anhydrous crystalline form of valacyclovir hydrochloride
WO2004106338A1 (en) * 2003-05-30 2004-12-09 Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. Novel crystalline forms of valacyclovir hydrochloride
WO2005000850A2 (en) * 2003-06-02 2005-01-06 Teva Pharmaceutical Industries, Ltd. Novel crystalline forms of valacyclovir hydrochloride
WO2005073233A1 (en) * 2004-01-21 2005-08-11 Teva Pharmaceutical Industries Ltd. Process for the preparation of valacyclovir hydrochloride
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
CN1976933A (zh) * 2004-06-30 2007-06-06 特瓦制药工业有限公司 减少晶体盐酸伐昔洛韦中的残留醇的方法
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
US20060178512A1 (en) * 2005-02-04 2006-08-10 Cheruthur Govindan Method for preparing amino acid esters of nucleoside analogues
ES2379804T3 (es) * 2005-05-25 2012-05-03 Eli Lilly And Company Ésteres de ciclopropanocarboxilato de aciclovir
EP1746098A1 (en) * 2005-07-21 2007-01-24 SOLMAG S.p.A. Valacyclovir polymorphs and a process for the preparation thereof
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US20070112193A1 (en) * 2005-11-14 2007-05-17 Khunt Mayur D Valacyclovir process
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
SG174054A1 (en) 2006-05-04 2011-09-29 Boehringer Ingelheim Int Polymorphs
PE20080251A1 (es) * 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
CN1903854B (zh) * 2006-08-09 2012-05-23 丽珠医药集团股份有限公司 一种合成盐酸伐昔洛韦的方法
US20080167325A1 (en) * 2006-12-27 2008-07-10 Bs Praveen Kumar Valacyclovir compositions
US20080281099A1 (en) * 2007-05-07 2008-11-13 Mayur Devjibhai Khunt Process for purifying valacyclovir hydrochloride and intermediates thereof
GB0710277D0 (en) * 2007-05-30 2007-07-11 Univ Birmingham Use of antivirals in the treatment of medical disorders
WO2009024542A2 (en) * 2007-08-17 2009-02-26 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
JPWO2009031576A1 (ja) * 2007-09-03 2010-12-16 味の素株式会社 バラシクロビル塩酸塩結晶の製造方法
US20090076039A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched valacyclovir
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
CN102123704B (zh) * 2008-08-15 2014-02-12 勃林格殷格翰国际有限公司 用于治疗fab-相关疾病的嘌呤衍生物
KR20110067096A (ko) 2008-09-10 2011-06-21 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 및 관련 상태를 치료하기 위한 병용 요법
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EA022310B1 (ru) 2008-12-23 2015-12-30 Бёрингер Ингельхайм Интернациональ Гмбх Солевые формы органического соединения
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
BR112012012641A2 (pt) 2009-11-27 2020-08-11 Boehringer Ingelheim International Gmbh TRATAMENTO DE PACIENTES DIABÉTICOS GENOTIPADOS COM INIBIDORES DE DPP-lVTAL COMO LINAGLIPTINA
KR101927068B1 (ko) 2010-05-05 2018-12-10 베링거 인겔하임 인터내셔날 게엠베하 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
WO2011158252A1 (en) 2010-06-15 2011-12-22 Matrix Laboratories Ltd Process for the preparation of valacyclovir hydrochloride polymorphic form ii
CA2803504C (en) 2010-06-24 2022-08-30 Boehringer Ingelheim International Gmbh A combination for diabetes therapy comprising linagliptin and a long-acting insulin
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
CN102584825B (zh) * 2011-01-17 2014-04-02 四川科伦药物研究有限公司 一种合成盐酸伐昔洛韦的方法
EP3517539B1 (en) 2011-07-15 2022-12-14 Boehringer Ingelheim International GmbH Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
EP2852592A4 (en) * 2011-11-25 2015-12-23 Piramal Entpr Ltd PROCESS FOR THE PREPARATION OF VALACYCLOVIR CHLORHYDRATE
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP4151218A1 (en) 2012-05-14 2023-03-22 Boehringer Ingelheim International GmbH Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害薬の医学的使用
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
CN110437231B (zh) * 2019-09-04 2022-04-29 上药康丽（常州）药业有限公司 一种盐酸伐昔洛韦无水晶型ⅰ的制备方法
WO2021209563A1 (en) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP160A (en) * 1987-08-15 1991-11-18 The Wellcome Foundation Ltd Therapeutic acyclic nucleosides.
DE69426880T2 (de) * 1993-06-10 2001-10-31 Rolabo S.L., Zaragoza Verfahren zur herstellung von aminosäureester von nukleosid analogen
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative

Also Published As

Publication number Publication date
EE03528B1 (et) 2001-10-15
IL116831A0 (en) 1996-05-14
EA000364B1 (ru) 1999-06-24
DK0804436T3 (da) 2005-12-27
GB9501178D0 (en) 1995-03-08
DE69635106T2 (de) 2006-06-08
AU702794B2 (en) 1999-03-04
IS4527A (is) 1997-07-15
KR19980701525A (ko) 1998-05-15
CA2210799A1 (en) 1996-07-25
JP3176633B2 (ja) 2001-06-18
FI973063L (fi) 1997-09-18
HUP9801836A2 (hu) 1999-05-28
NZ298851A (en) 1999-01-28
YU3396A (sh) 1998-12-23
AU4453996A (en) 1996-08-07
IL116831A (en) 1998-10-30
GEP20001940B (en) 2000-02-05
PL321326A1 (en) 1997-12-08
EP0804436A1 (en) 1997-11-05
ATE302777T1 (de) 2005-09-15
HUP9801836A3 (en) 1999-06-28
WO1996022291A1 (en) 1996-07-25
NO315558B1 (no) 2003-09-22
CA2210799C (en) 2008-06-10
EP0804436B1 (en) 2005-08-24
SI0804436T1 (sl) 2006-02-28
RO118693B1 (ro) 2003-09-30
CN1179159A (zh) 1998-04-15
NO973326L (no) 1997-09-16
FI973063A0 (fi) 1997-07-18
IN182468B (enExample) 1999-04-17
DE69635106D1 (de) 2005-09-29
AP9701058A0 (en) 1997-10-31
SK285329B6 (sk) 2006-11-03
ZA96449B (en) 1996-08-07
OA10499A (en) 2002-04-10
NO973326D0 (no) 1997-07-18
CZ229497A3 (en) 1997-12-17
CZ297065B6 (cs) 2006-08-16
BR9606768A (pt) 1997-12-30
HU222993B1 (hu) 2004-01-28
PL182175B1 (pl) 2001-11-30
AP662A (en) 1998-08-19
HRP960024A2 (en) 1997-10-31
JPH11503718A (ja) 1999-03-30
CY2531B1 (en) 2006-04-12
SK96597A3 (en) 1998-02-04
EE9700175A (et) 1998-02-16
AR002270A1 (es) 1998-03-11
MX9705462A (es) 1997-10-31
IS2268B (is) 2007-07-15
UA46001C2 (uk) 2002-05-15
UY25779A1 (es) 2000-08-21
EA199700124A1 (ru) 1997-12-30
RS49518B (sr) 2006-10-27
KR100376074B1 (ko) 2003-06-02
TR199700656T1 (xx) 1998-03-21
US6107302A (en) 2000-08-22
BG101833A (bg) 1998-04-30
FI973063A7 (fi) 1997-09-18
HRP960024B1 (en) 2005-08-31
CN1049893C (zh) 2000-03-01
BG63393B1 (bg) 2001-12-29

Similar Documents

Publication Publication Date Title
ES2248806T3 (es) Derivado de la guanina.
KR100412298B1 (ko) 콜로이드이산화규소를함유하는발라시클로비르정제
JP4452034B2 (ja) アデフォビルジピボキシルを調製するための方法
ES2206403T3 (es) Nueva forma cristalina de acido n-(4-(2-(2-amino-4,7dihidro-4.oxo-3h-pirrolo(2,3-d)pirimidin-5-il)etil(benzoil)-l-glutamico y procedimiento de preparacion.
ES2216503T3 (es) Nuevas formas cristalinas de un compuesto antivirico de bencimidazol.
ES2324654T3 (es) Derivado de hemisulfato de azido citosina cristalino anhidro.
JP4097698B2 (ja) 一日一回の投与による陰部ヘルペス治療用医薬の製造のためのバラシクロビールの使用
ES2281594T3 (es) Procedimiento para la preparacion de adsorbatos de atorvastatina en polvo de flujo libre.
MXPA97005462A (en) Derived from guan
HK1003055A1 (en) Guanine derivative
HK1003055B (en) Guanine derivative
MXPA97005459A (en) Valaciclovir tablets containing silicon dioxide color